Market Cap
CA$1.8b
Last Updated
2020/10/21 00:44 UTC
Data Sources
Company Financials +
Executive Summary
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Aphria's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APHA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-21.4%
APHA
1.4%
CA Pharmaceuticals
-0.9%
CA Market
1 Year Return
-8.6%
APHA
-19.8%
CA Pharmaceuticals
-4.2%
CA Market
Return vs Industry: APHA exceeded the Canadian Pharmaceuticals industry which returned -19.8% over the past year.
Return vs Market: APHA underperformed the Canadian Market which returned -4.2% over the past year.
Shareholder returns
| APHA | Industry | Market | |
|---|---|---|---|
| 7 Day | -21.4% | 1.4% | -0.9% |
| 30 Day | 2.2% | 14.8% | 1.2% |
| 90 Day | -11.5% | 11.7% | 1.4% |
| 1 Year | -8.6%-8.6% | -19.8%-19.8% | -0.7%-4.2% |
| 3 Year | -12.2%-12.2% | -15.3%-16.1% | 6.6%-3.8% |
| 5 Year | 409.2%409.2% | 170.4%169.0% | 34.2%13.5% |
Price Volatility Vs. Market
How volatile is Aphria's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Have Insiders Been Selling Aphria Inc (TSE:APHA) Shares?1 year ago | Simply Wall St
What You Must Know About Aphria Inc's (TSE:APHA) Financial Health1 year ago | Simply Wall St
Why Aphria Inc's (TSE:APHA) High P/E Ratio Isn't Necessarily A Bad ThingValuation
Is Aphria undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APHA (CA$6.06) is trading below our estimate of fair value (CA$15.72)
Significantly Below Fair Value: APHA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APHA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: APHA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APHA is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Aphria forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
58.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APHA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: APHA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: APHA's is expected to become profitable in the next 3 years.
Revenue vs Market: APHA's revenue (23.6% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: APHA's revenue (23.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APHA's Return on Equity is forecast to be low in 3 years time (8%).
Next Steps
Past Performance
How has Aphria performed over the past 5 years?
-38.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APHA is currently unprofitable.
Growing Profit Margin: APHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APHA is unprofitable, and losses have increased over the past 5 years at a rate of 38.1% per year.
Accelerating Growth: Unable to compare APHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).
Return on Equity
High ROE: APHA has a negative Return on Equity (-5.74%), as it is currently unprofitable.
Next Steps
Financial Health
How is Aphria's financial position?
Financial Position Analysis
Short Term Liabilities: APHA's short term assets (CA$891.5M) exceed its short term liabilities (CA$166.0M).
Long Term Liabilities: APHA's short term assets (CA$891.5M) exceed its long term liabilities (CA$474.4M).
Debt to Equity History and Analysis
Debt Level: APHA's debt to equity ratio (22.6%) is considered satisfactory.
Reducing Debt: APHA's debt to equity ratio has increased from 0.9% to 22.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APHA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if APHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Aphria current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APHA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Irwin Simon (62 yo)
1.58yrs
Tenure
CA$18,623,184
Compensation
Mr. Irwin D. Simon has been Chairman of Aphria Inc. since December 27, 2018 and serves as its Chief Executive Officer since February 2020 and served as its Interim Chief Executive Officer from March 01, 20 ...
CEO Compensation Analysis
Compensation vs Market: Irwin's total compensation ($USD14.19M) is above average for companies of similar size in the Canadian market ($USD2.07M).
Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.58yrs | CA$18.62m | no data | |
| Chief Financial Officer | 4.83yrs | CA$1.51m | 0.11% CA$ 1.9m | |
| Chief Legal Officer | 2.33yrs | CA$1.89m | no data | |
| Chief Operating Officer of Aphria Leamington | 1.42yrs | CA$2.94m | no data | |
| Chief Strategy Officer | 0.92yr | CA$2.27m | no data | |
| Vice President of Investor Relations | 2.08yrs | no data | no data | |
| Senior Vice President of Sales & Marketing | 0.33yr | no data | no data | |
| Vice President of Corporate Human Resources | 1.42yrs | no data | no data | |
| Special Advisor | 1.58yrs | CA$1.00m | no data | |
| Special Advisor | 1.58yrs | CA$457.89k | no data | |
| Chief Corporate Affairs Officer | 0.92yr | no data | no data | |
| Managing Director of Aphria Germany GmbH | no data | CA$691.96k | no data |
1.6yrs
Average Tenure
63.5yo
Average Age
Experienced Management: APHA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.58yrs | CA$18.62m | no data | |
| Independent Director | 1.5yrs | CA$299.99k | 0.0017% CA$ 30.3k | |
| Independent Director | 1.5yrs | CA$299.99k | no data | |
| Independent Director | 2.08yrs | CA$302.10k | no data | |
| Independent Director | 1.92yrs | CA$299.99k | 0.00026% CA$ 4.6k | |
| Independent Director | 0.92yr | CA$158.15k | no data | |
| Independent Vice Chairman & Lead Director | 0.75yr | CA$357.47k | 0.0065% CA$ 113.1k |
1.5yrs
Average Tenure
61yo
Average Age
Experienced Board: APHA's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.8%.
Top Shareholders
Company Information
Aphria Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aphria Inc.
- Ticker: APHA
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.753b
- Shares outstanding: 289.34m
- Website: https://aphriainc.com
Number of Employees
Location
- Aphria Inc.
- 98 Talbot Street West
- Leamington
- Ontario
- N8H 1M8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| APHA | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Dec 2014 |
| APHA | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Dec 2014 |
| 10E | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Dec 2014 |
| 0UI4 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Dec 2014 |
Biography
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, an ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/21 00:44 |
| End of Day Share Price | 2020/10/20 00:00 |
| Earnings | 2020/08/31 |
| Annual Earnings | 2020/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.